Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial

Immune dysregulation has been reported in schizophrenia spectrum disorders (SSD). In the past decade, several trials using anti-inflammatory agents for treatment of SSD have been completed, with so far limited success. One such anti-inflammatory agent used is simvastatin. A recent, large-scale, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Aichholzer, Mareike, Gangadin, Shiral S., Sommer, Iris E.C., Wijkhuis, Annemarie, de Witte, Lot D., Kahn, René S., Bahn, Sabine, Drexhage, Hemmo A., Schiweck, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668621/
https://www.ncbi.nlm.nih.gov/pubmed/36405425
http://dx.doi.org/10.1016/j.bbih.2022.100551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668621/
https://www.ncbi.nlm.nih.gov/pubmed/36405425
http://dx.doi.org/10.1016/j.bbih.2022.100551

Ejemplares similares